Ligand Pharmaceuticals Income Statement

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Mar '25 Mar 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Revenue	25,838	23,341	13,006	6,696
Revenue Growth (YoY)	71.02%	79.47%	94.23%	-
Cost of Revenue	23.22	7.95	-	-
Gross Profit	25,815	23,333	13,006	6,696
Selling, General & Admin	23,295	20,991	14,737	10,520
Research & Development	567.71	548.33	595.72	173.86
Other Operating Expenses	533.21	521.93	237.49	147.34
Operating Expenses	25,376	22,980	16,239	11,260
Operating Income	439.23	352.46	-3,233	-4,564
Interest Expense	-654.89	-649.76	-1,916	-1,355
Interest & Investment Income	263.15	210.01	192.52	102.24
Currency Exchange Gain (Loss)	-8.05	-10.74	0.73	-2.41
Other Non Operating Income (Expenses)	565.87	576.54	-7,634	-13,142
EBT Excluding Unusual Items	605.31	478.51	-12,590	-18,961
Gain (Loss) on Sale of Investments	-46.7	-46.41	-25	-178.8
Pretax Income	558.61	432.1	-12,615	-19,140
Income Tax Expense	280.04	280.33	-	12.08
Net Income	278.58	151.77	-12,615	-19,152
Net Income to Common	278.58	151.77	-12,615	-19,152
Shares Outstanding (Basic)	16	13	5	2
Shares Outstanding (Diluted)	22	16	5	2
Shares Change (YoY)	359.92%	241.85%	100.00%	-
EPS (Basic)	17.00	11.49	-2661.12	-8080.04
EPS (Diluted)	-14.68	-27.49	-2661.12	-8080.04
Free Cash Flow	712.35	1,197	-2,230	-3,085
Free Cash Flow Per Share	32.67	73.88	-470.35	-1301.39
Gross Margin	99.91%	99.97%	100.00%	100.00%
Operating Margin	1.70%	1.51%	-24.86%	-68.16%
Profit Margin	1.08%	0.65%	-97.00%	-286.02%
Free Cash Flow Margin	2.76%	5.13%	-17.14%	-46.07%
EBITDA	1,419	1,272	-2,569	-4,145
EBITDA Margin	5.49%	5.45%	-19.76%	-61.90%
D&A For EBITDA	980.26	919.45	663.61	419.08
EBIT	439.23	352.46	-3,233	-4,564
EBIT Margin	1.70%	1.51%	-24.86%	-68.16%
Effective Tax Rate	50.13%	64.88%	-	-
Advertising Expenses	-	2,600	2,307	2,064

Source: S&P Global Market Intelligence. Standard template. Financial Sources.